Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be where the field is headed...


Business Insider | 2018-05-24 14:58 UTC

BI PRIME: Researchers at Pfizer are shifting their attention toward combining immune system-acting drugs with targeted therapies that act on genetic mutations in cancer patients to see if more people respond.

By Anonymous Submission on 2018-05-24 15:05 UTC
  • Need an account?  
    or